Rigel Pharmaceuticals, Inc.
2,3-Disubstituted pyridine compounds as TGF-.beta. inhibitors and methods of use

Last updated:

Abstract:

The invention described herein comprises compounds and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds inhibit signaling by a member of the TGF-.beta. superfamily such as Nodal or Activin.

Status:
Grant
Type:

Utility

Filling date:

16 Jan 2019

Issue date:

8 Dec 2020